fusion protein

Rilematovir (JNJ-678) 是一种融合蛋白抑制剂，具有抗病毒活性和低细胞毒性。 Rilematovir 可用于呼吸道合胞病毒治疗的研究。

SNAP-fusion protein ligand-1 (Compound 1i) 是一种PROTAC的靶蛋白配体 (Ligand for Target Protein for PROTAC)，可用于合成PROTAC VHL-SNAP2-5C。

Shield-1 是 FK506 结合蛋白 12 (FKBP) 的特异性、高亲和力和细胞渗透性配体，通过与突变的 FKBP (mtFKBP) 结合来逆转不稳定性，允许 mtFKBP 融合蛋白的条件表达。

Ziresovir (RO-0529) 是一种呼吸道合胞病毒融合蛋白 (RSV F) 抑制剂，抑制 RSV 活性，可用于研究合胞病毒感。

Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extracellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). It is a selective T-cell co-stimulation modulator and a protein drug for au

AP20187 (B/B Homodimerizer) 是一种细胞渗透性配体，用于二聚化 FK506 结合蛋白 (FKBP) 融合蛋白。它启动生物信号级联和基因表达或破坏蛋白质-蛋白质相互作用。

Enzomenib (DSP5336) 是一种针对多发性内分泌腺瘤 (MEN) 基因所编码的menin蛋白的抑制剂。它能阻断menin蛋白与混合谱系白血病 (MLL) 融合蛋白之间的相互作用，应用于血液系统恶性肿瘤的研究领域。

PROTAC ALK degrader-3 (4B) 作为一种基于PROTACs的降解剂，其特点是具有口服活性，能对Karpas 299细胞中的ALK融合蛋白进行持久的降解，并强烈抑制下游通路，IC50为119.33 nM。此化合物展现出明显的抗肿瘤活性。

UR-AK49（compound 11）是一种激活人类组胺H1和H2受体的化合物。在利用Sf9昆虫细胞表达的hH2R-Gsalpha融合蛋白进行的GTP酶活性测定中，UR-AK49的EC50值为23 nM。该化合物主要用于神经科学领域的研究。

CL-A3-7 作为一种病毒-细胞融合抑制剂，专门针对RSVF蛋白，通过阻止病毒和宿主细胞IGF1R之间的交互作用来发挥效能。该化合物不仅能有效地阻断野生型RSV的感染，还对K394R变异株也有显著的抑制作用，因此极具潜力用于开发抗RSV药物及进行耐药性的研究。

GNF-2-deg 是一种 PROTAC 降解剂，用于降解登革热病毒包膜蛋白 (DENV E 蛋白)，其 DC50 为 0.83 μM。通过抑制 E 蛋白介导的膜融合，GNF-2-deg 阻止病毒进入，并通过蛋白降解抑制病毒体的产生，对 DENV 2 展现抗病毒活性，EC90 为 3.5 μM。同时，GNF-2-deg 对 ZIKV、JEV、WNV 和 YFV 也具有抗病毒活性，EC90 范围为 1.96-7.79 μM。

RUNX1/ETO-IN-1 是一种抑制RUNX1-ETO致癌融合蛋白的药物，对NHR2寡聚化结构域具有特异性作用。此化合物直接结合于NHR2，并具有KD,app= 39 μM的结合亲和力。通过诱导细胞凋亡和促进分化，RUNX1/ETO-IN-1 在RUNX1/ETO易位型急性髓系白血病 (AML) 细胞中表现出抗白血病活性。此外，在生理pH条件下，RUNX1/ETO-IN-1 基本不带电荷，从而具备出色的细胞膜渗透性。

CC-647 是分子胶(molecular glue)调节剂，专注于靶向Cereblon(CRBN) E3 泛素连接酶。它增强了 CRBN 与 ZBTB16 及其致癌融合蛋白 RARα-ZBTB16 的相互作用，对 ZBTB16 的DC50为 103 nM。CC-647 有潜力用于研究与 ZBTB16-RARα 相关的急性早幼粒细胞白血病(APL)。

VHL-SNAP2-5C 是一种利用自标记蛋白 SNAP 标签的 SNAP 融合蛋白PROTAC降解剂。通过内源性标记的 VHL-SNAP2-5C，可以实现对SNAP-融合蛋白（如 CLCa 和 EGFP）的可视化及选择性去除。

PROTACBET Degrader-13 (Compound 34) 是一种基于TRIM21的PROTAC (TRIMTAC) 降解剂，靶向BET。它能显著降解PML-eGFP-BRD4融合蛋白，导致EGFP+核点几乎完全消失，其EC50为1.4 μM。

Glycoprotein B is a peptide with the sequence H2N-Ser-Ser-Ile-Glu-Phe-Ala-Arg-Leu-OH, MW= 922.04. glycoprotein B is a viral glycoprotein that is involved in the viral cell entry of Herpes simplex virus. The herpesvirus glycoprotein B is the most highly c

RV521 is a highly effective fusion inhibitor. It designed to treat RSV disease by the target of a surface protein that mediates RSV binding to cellular receptors.

JNJ-2408068 is an inhibitor of respiratory syncytial virus (RSV). JNJ-2408068 exhibited potent antiviral activity with EC50 of 2.1 nM. A similar inhibitory effect was observed in a RSV-mediated cell fusion assay (EC50= 0.9 nM). JNJ-2408068 interferes with

SLUPP-225 is an efflux pump inhibitor (EPI) by interacting with the membrane fusion protein AcrA, a critical component of the AcrAB-TolC efflux pump in Escherichia coli.

SLUPP-417 is an efflux pump inhibitor (EPI) by interacting with the membrane fusion protein AcrA, a critical component of the AcrAB-TolC efflux pump in Escherichia coli.

Degrader of MTH1 fusion proteins for use within the aTAG system. Comprises a ligand selective for MTH1, a linker and the cereblon-binding ligand Thalidomide . Induces highly potent and selective degradation of fusion proteins after a 4 h incubation (DC50 = 0.27 nM; Dmax = 92.1%). Cell-permeable. Suitable for in vitro and in vivo applications. Mouse DMPK properties are provided in the supplementary file (see below). (MTH1 can be expressed as a fusion with a target protein of interest using genome engineering techniques via CRISPR-mediated locus-specific knock-in - see protocol for more information.) 0

Degrader of MTH1 fusion proteins for use within the aTAG system. Comprises a ligand selective for MTH1, a linker and the cereblon-binding ligand Thalidomide . Induces highly potent and selective degradation of fusion proteins after a 4 h incubation (DC50 = 0.34 nM; Dmax = 93.14%). Cell-permeable. Suitable for in vitro and in vivo applications. Mouse DMPK properties are provided in the supplementary file (see below). (MTH1 can be expressed as a fusion with a target protein of interest using genome engineering techniques via CRISPR-mediated locus-specific knock-in - see protocol for more information.) 0

Degrader targeting mutant FKBP12F36V fusion proteins. Comprises a ligand selective for F36V single-point mutated FKBP12, a linker and a von Hippel-Lindau (VHL)-binding ligand. Induces potent and selective degradation of FKBP12F36V fusion proteins in vitro and in vivo. Selectively degrades FKBP12F36V-EWS/FLI fusion proteins and inhibits cell proliferation in FKBP12F36V-EWS/FLI-expressing Ewing sarcoma cells. Hydrochloride salt (Cat.No. 7374) available; suitable for in vivo use. Negative control dTAGV-1-NEG (Cat. No. 6915) also available. FKBP12F36V can be expressed as a fusion with a target protein of interest using genome engineering techniques, via transgene expression or CRISPR-mediated locus-specific knock-in. Custom knock-in cell lines for the dTAG and aTAG platforms are available from our sister brand R&D Systems. Email TPD@bio-techne.com to enquire. Plasmid vectors for the lentiviral expression and CRISPR-mediated knock-in of FKBP12F36V are available from Addgene.

pep2m aceate 是 GluR2 亚基 C 端与 N-乙基马来酰亚胺敏感融合蛋白相互作用的肽抑制剂。